Officials toss Genentech antibody patent

Genentech says the U.S. Patent Office has rejected a patent covering the way it uses recombinant DNA technology to make antibodies. The biotech giant says it uses the 415 patent in making a number of therapies, has licensing agreements on the technology covered in the patent and earns royalties on claims to the patent. The Patent Office's decision came after Genentech asked it to reexamine the issue after patent officials originally rejected 36 patent claims. Genentech says it may appeal.

- see this release
- check out the AP story

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.